You are here

Enhertu

Enhertu offers survival benefits in Phase II solid tumour trial

Enhertu offers survival benefits in Phase II solid tumour trial

Clinical Trials Arena

clinical trials

Flag link:

AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors

AstraZeneca stock slides as pivotal lung cancer readout on Daiichi-partnered ADC spooks investors

Fierce Biotech

antibody-drug conjugate

clinical trials

non-small cell lung cancer

Flag link:

AstraZeneca study points to new uses for targeted cancer drug Enhertu

AstraZeneca study points to new uses for targeted cancer drug Enhertu

BioPharma Dive

cervical cancer

Flag link:

AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps

AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps

Endpoints

clinical trials

Flag link:

The first big test for the son of Enhertu

The first big test for the son of Enhertu

EP Vantage

datopotamab deruxtecan

clinical trials

Flag link:

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

Fierce Pharma

Flag link:

The problem with Her2-low testing

The problem with Her2-low testing

EP Vantage

HER2-low breast cancer

Flag link:

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

Daiichi Sankyo sets new highs for AstraZeneca-partnered cancer drug Enhertu

Endpoints

non-small cell lung cancer

Flag link:

Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

Roche nets FDA approval for HER2-low breast cancer test paired with AstraZeneca-Daiichi's Enhertu

Fierce Biotech

HER2-low breast cancer

Flag link:

FDA approves AstraZeneca, Daiichi drug in breast cancer first

FDA approves AstraZeneca, Daiichi drug in breast cancer first

BioPharma Dive

HER2-low breast cancer

Flag link:

AstraZeneca wins two recommendations, one priority review

AstraZeneca wins two recommendations, one priority review

Morningstar

Flag link:

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

Daiichi Sankyo willfully infringed Seagen patent in creating Enhertu, court rules

Fierce Pharma

Flag link:

This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca

This Cancer Drug's News Could Mean Another Blockbuster for AstraZeneca

Motley Fool

Flag link:

ASCO22: Enhertu aces key HER2-low test in breast cancer

ASCO22: Enhertu aces key HER2-low test in breast cancer

Pharmaforum

HER2-low breast cancer

Flag link:

Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

Former AstraZeneca exec committed insider trading on landmark 2019 Enhertu deal, SEC alleges

Endpoints

insider trading

Flag link:

3 cancer drug studies to watch at next month’s ASCO meeting

3 cancer drug studies to watch at next month’s ASCO meeting

BioPharma Dive

Gilead Sciences

Flag link:

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

FDA Approves AstraZeneca, Daiichi Sankyo’s ENHERTU in Breast Cancer

Contract Pharma

HER2+ breast cancer

Flag link:

FDA starts speedy review of Enhertu in lung cancer

FDA starts speedy review of Enhertu in lung cancer

Pharmaforum

non-small cell lung cancer

Flag link:

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Seagen scores $41.8M in Enhertu patent case against Daiichi Sankyo

Fierce Pharma

Flag link:

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Big day for AZ, Daiichi as Enhertu aces HER2-low breast cancer trial

Pharmaforum

clinical trials

HER2-low breast cancer

Flag link:

Pages